Leading Companies Pioneering Innovation and Growth in the Brain Tumor Drugs Market

The brain tumor drugs market is on track for significant expansion over the coming years, driven by advancements in medical technology and growing investment in oncology research. As new therapies emerge and healthcare spending increases globally, the market is poised for notable growth through 2030. Let's explore the market's size projections, key players, emerging trends, and segmentation outlook to better understand this evolving landscape.

Brain Tumor Drugs Market Size Growth Outlook Through 2030
The brain tumor drugs market is expected to reach $5.5 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.6%. Several factors contribute to this growth during the forecast period, including the rise of precision medicine, the integration of artificial intelligence in drug discovery, expanded research and development in oncology, increased healthcare expenditure, and wider adoption of targeted therapies. Key trends shaping the market include personalized chemotherapy regimens, expanded applications of hormone therapy, advancements in pain management medications, increased use of anticonvulsants for symptom control, and growth in the pipeline of brain tumor drugs.

Download a free sample of the brain tumor drugs market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2588&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Factors Fueling Growth in the Brain Tumor Drugs Market
The development and adoption of precision medicine are playing a vital role in propelling the brain tumor drugs market forward. By tailoring treatments based on genetic and molecular profiles, therapies are becoming more targeted and effective, leading to better patient outcomes.
Additionally, the growing incorporation of artificial intelligence within drug discovery processes is accelerating the identification and development of innovative therapies. This technological integration helps optimize clinical trials and enhance treatment personalization, thus driving market expansion.

Leading Companies Shaping the Brain Tumor Drugs Industry
The brain tumor drugs market includes a wide range of prominent players, such as F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co. Ltd., Emcure Pharmaceuticals Limited, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt. Ltd, Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Astellas Pharma Inc, Otsuka Pharmaceutical Co. Ltd, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratórios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, and Adcock Ingram.

View the full brain tumor drugs market report:
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Recent Acquisition Highlighting Market Strategy
In September 2024, Stryker Corporation, a US-based medical technology firm, acquired NICO Corporation for an undisclosed sum. This strategic acquisition aims to strengthen Stryker's portfolio in minimally invasive neurosurgical solutions, particularly for brain tumor removal and treatment of intracerebral hemorrhage. NICO Corporation, also based in the US, specializes in developing minimally invasive neurosurgical devices. This move is expected to improve patient outcomes and drive growth within Stryker's neurotechnology offerings.

Emerging Trends in the Brain Tumor Drugs Market
Major players in the brain tumor drugs field are focusing on advanced therapies such as targeted RAF kinase inhibitors. These drugs address the growing demand for precision oncology treatments by specifically targeting genetic mutations found in brain tumors. This selective approach helps minimize systemic toxicity and enhances patient outcomes compared to traditional chemotherapy.
For example, in November 2025, US biotech company Day One Biopharmaceuticals introduced OJEMDA (tovorafenib), a novel treatment for pediatric patients with relapsed or refractory low-grade gliomas harboring BRAF fusions or V600 mutations. This once-weekly, orally administered drug penetrates the brain effectively and selectively inhibits mutant RAF proteins. Its high specificity reduces systemic side effects typical of conventional chemotherapy, making it well suited for children and marking a significant advancement in personalized brain tumor treatment.

Detailed Segmentation of the Brain Tumor Drugs Market
This market report organizes the brain tumor drugs industry into key segments:
1) By Drugs: Temozolomide, Bevacizumab, and Other Drugs
2) By End User: Hospital Pharmacies, Retail Pharmacies or Drug Stores, and Other End Users
3) By Mechanism of Action: Chemotherapy Agents, Targeted Therapy, and Hormone Therapy

Further breakdown includes:
- Temozolomide: Oral and Injectable formulations
- Bevacizumab: Monoclonal antibody therapy and combination therapy with chemotherapy
- Other Drugs: Including Carmustine, Lomustine, Etoposide, Irinotecan, and Novantrone (Mitoxantrone)

This segmentation provides a comprehensive view of the drug types, usage settings, and therapeutic mechanisms central to the brain tumor drugs market's ongoing evolution.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.